Sanofi-aventis has entered an agreement to acquire BiPar Sciences, Inc., a privately held U.S. biopharmaceutical company developing tumor-selective approaches for the treatment of cancer, for as much as $500 million. Under the agreement, the purchase price will depend on the achievement of development milestones related to BiPar’s leading drug candidate, BSI-201, currently in Phase II trials for breast and ovarian cancer. BiPar is developing tumor-selective cancer treatments in the emer...